Terms: = Breast cancer AND MAP3K1, ENSG00000095015, 4214, Q13233, MEKK1, MEKK, MAPKKK1 AND Prognosis
19 results:
1. map3k1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen SJ; Viale G; Nik-Zainal S; Savas P; Kammler R; Dell'Orto P; Biasi O; Degasperi A; Brown LC; Láng I; MacGrogan G; Tondini C; Bellet M; Villa F; Bernardo A; Ciruelos E; Karlsson P; Neven P; Climent M; Müller B; Jochum W; Bonnefoi H; Martino S; Davidson NE; Geyer C; Chia SK; Ingle JN; Coleman R; Solbach C; Thürlimann B; Colleoni M; Coates AS; Goldhirsch A; Fleming GF; Francis PA; Speed TP; Regan MM; Loi S
Ann Oncol; 2023 Apr; 34(4):397-409. PubMed ID: 36709040
[TBL] [Abstract] [Full Text] [Related]
3. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.
Mueller SH; Lai AG; Valkovskaya M; Michailidou K; Bolla MK; Wang Q; Dennis J; Lush M; Abu-Ful Z; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baert T; Freeman LEB; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Brenner H; Brucker SY; Buys SS; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Choi JY; Chung WK; ; Colonna SV; ; Cornelissen S; Couch FJ; Czene K; Daly MB; Devilee P; Dörk T; Dossus L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Engel C; Evans DG; Fasching PA; Fletcher O; Flyger H; Gago-Dominguez M; Gao YT; García-Closas M; García-Sáenz JA; Genkinger J; Gentry-Maharaj A; Grassmann F; Guénel P; Gündert M; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hall P; Harkness EF; Harrington PA; Hartikainen JM; Hartman M; Hein A; Ho WK; Hooning MJ; Hoppe R; Hopper JL; Houlston RS; Howell A; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakubowska A; Janni W; John EM; Jones ME; Jung A; Kaaks R; Kang D; Khusnutdinova EK; Kim SW; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kubelka-Sabit K; Kurian AW; Kwong A; Lacey JV; Lambrechts D; Le Marchand L; Li J; Linet M; Lo WY; Long J; Lophatananon A; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Menon U; Muir K; Murphy RA; Nevanlinna H; Newman WG; Niederacher D; O'Brien KM; Obi N; Offit K; Olopade OI; Olshan AF; Olsson H; Park SK; Patel AV; Patel A; Perou CM; Peto J; Pharoah PDP; Plaseska-Karanfilska D; Presneau N; Rack B; Radice P; Ramachandran D; Rashid MU; Rennert G; Romero A; Ruddy KJ; Ruebner M; Saloustros E; Sandler DP; Sawyer EJ; Schmidt MK; Schmutzler RK; Schneider MO; Scott C; Shah M; Sharma P; Shen CY; Shu XO; Simard J; Surowy H; Tamimi RM; Tapper WJ; Taylor JA; Teo SH; Teras LR; Toland AE; Tollenaar RAEM; Torres D; Torres-Mejía G; Troester MA; Truong T; Vachon CM; Vijai J; Weinberg CR; Wendt C; Winqvist R; Wolk A; Wu AH; Yamaji T; Yang XR; Yu JC; Zheng W; Ziogas A; Ziv E; Dunning AM; Easton DF; Hemingway H; Hamann U; Kuchenbaecker KB
Genome Med; 2023 Jan; 15(1):7. PubMed ID: 36703164
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in breast cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract] [Full Text] [Related]
5. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in breast cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract] [Full Text] [Related]
6. Identifying Genomic Alterations in Patients With Stage IV breast cancer Using MammaSeq: An International Collaborative Study.
Shah OS; Soran A; Sahin M; Knapick BA; Ugras S; Celik E; Lucas PC; Lee AV
Clin Breast Cancer; 2021 Jun; 21(3):210-217. PubMed ID: 33191115
[TBL] [Abstract] [Full Text] [Related]
7. Pathway Mutations in breast cancer Using Whole-Exome Sequencing.
Chang YS; Chang CM; Lin CY; Chao DS; Huang HY; Chang JG
Oncol Res; 2020 Mar; 28(2):107-116. PubMed ID: 31575382
[TBL] [Abstract] [Full Text] [Related]
8. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Liang X; Briaux A; Becette V; Benoist C; Boulai A; Chemlali W; Schnitzler A; Baulande S; Rivera S; Mouret-Reynier MA; Bouvet LV; De La Motte Rouge T; Lemonnier J; Lerebours F; Callens C
J Hematol Oncol; 2018 Oct; 11(1):124. PubMed ID: 30305115
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL; Spies NC; Anurag M; Griffith M; Luo J; Tu D; Yeo B; Kunisaki J; Miller CA; Krysiak K; Hundal J; Ainscough BJ; Skidmore ZL; Campbell K; Kumar R; Fronick C; Cook L; Snider JE; Davies S; Kavuri SM; Chang EC; Magrini V; Larson DE; Fulton RS; Liu S; Leung S; Voduc D; Bose R; Dowsett M; Wilson RK; Nielsen TO; Mardis ER; Ellis MJ
Nat Commun; 2018 Sep; 9(1):3476. PubMed ID: 30181556
[TBL] [Abstract] [Full Text] [Related]
10. An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
Győrffy B; Pongor L; Bottai G; Li X; Budczies J; Szabó A; Hatzis C; Pusztai L; Santarpia L
Br J Cancer; 2018 Apr; 118(8):1107-1114. PubMed ID: 29559730
[TBL] [Abstract] [Full Text] [Related]
11. Polymorphisms of ESR1, UGT1A1, HCN1, map3k1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract] [Full Text] [Related]
12. A map3k1 SNP predicts survival of gastric cancer in a Chinese population.
Wei X; Zhang E; Wang C; Gu D; Shen L; Wang M; Xu Z; Gong W; Tang C; Gao J; Chen J; Zhang Z
PLoS One; 2014; 9(4):e96083. PubMed ID: 24759887
[TBL] [Abstract] [Full Text] [Related]
13. The molecular diversity of Luminal A breast tumors.
Ciriello G; Sinha R; Hoadley KA; Jacobsen AS; Reva B; Perou CM; Sander C; Schultz N
Breast Cancer Res Treat; 2013 Oct; 141(3):409-20. PubMed ID: 24096568
[TBL] [Abstract] [Full Text] [Related]
14. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.
Shan J; Mahfoudh W; Dsouza SP; Hassen E; Bouaouina N; Abdelhak S; Benhadjayed A; Memmi H; Mathew RA; Aigha II; Gabbouj S; Remadi Y; Chouchane L
Breast Cancer Res Treat; 2012 Oct; 135(3):715-24. PubMed ID: 22910930
[TBL] [Abstract] [Full Text] [Related]
15. Sequence analysis of mutations and translocations across breast cancer subtypes.
Banerji S; Cibulskis K; Rangel-Escareno C; Brown KK; Carter SL; Frederick AM; Lawrence MS; Sivachenko AY; Sougnez C; Zou L; Cortes ML; Fernandez-Lopez JC; Peng S; Ardlie KG; Auclair D; Bautista-Piña V; Duke F; Francis J; Jung J; Maffuz-Aziz A; Onofrio RC; Parkin M; Pho NH; Quintanar-Jurado V; Ramos AH; Rebollar-Vega R; Rodriguez-Cuevas S; Romero-Cordoba SL; Schumacher SE; Stransky N; Thompson KM; Uribe-Figueroa L; Baselga J; Beroukhim R; Polyak K; Sgroi DC; Richardson AL; Jimenez-Sanchez G; Lander ES; Gabriel SB; Garraway LA; Golub TR; Melendez-Zajgla J; Toker A; Getz G; Hidalgo-Miranda A; Meyerson M
Nature; 2012 Jun; 486(7403):405-9. PubMed ID: 22722202
[TBL] [Abstract] [Full Text] [Related]
16. The role of genetic breast cancer susceptibility variants as prognostic factors.
Fasching PA; Pharoah PD; Cox A; Nevanlinna H; Bojesen SE; Karn T; Broeks A; van Leeuwen FE; van't Veer LJ; Udo R; Dunning AM; Greco D; Aittomäki K; Blomqvist C; Shah M; Nordestgaard BG; Flyger H; Hopper JL; Southey MC; Apicella C; Garcia-Closas M; Sherman M; Lissowska J; Seynaeve C; Huijts PE; Tollenaar RA; Ziogas A; Ekici AB; Rauh C; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Andrulis IL; Ozcelik H; Mulligan AM; Glendon G; Hall P; Czene K; Liu J; Chang-Claude J; Wang-Gohrke S; Eilber U; Nickels S; Dörk T; Schiekel M; Bremer M; Park-Simon TW; Giles GG; Severi G; Baglietto L; Hooning MJ; Martens JW; Jager A; Kriege M; Lindblom A; Margolin S; Couch FJ; Stevens KN; Olson JE; Kosel M; Cross SS; Balasubramanian SP; Reed MW; Miron A; John EM; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Burwinkel B; Marme F; Schneeweiss A; Sohn C; Chenevix-Trench G; ; Lambrechts D; Dieudonne AS; Hatse S; van Limbergen E; Benitez J; Milne RL; Zamora MP; Pérez JI; Bonanni B; Peissel B; Loris B; Peterlongo P; Rajaraman P; Schonfeld SJ; Anton-Culver H; Devilee P; Beckmann MW; Slamon DJ; Phillips KA; Figueroa JD; Humphreys MK; Easton DF; Schmidt MK
Hum Mol Genet; 2012 Sep; 21(17):3926-39. PubMed ID: 22532573
[TBL] [Abstract] [Full Text] [Related]
17. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
[TBL] [Abstract] [Full Text] [Related]
18. Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.
Riaz M; Berns EM; Sieuwerts AM; Ruigrok-Ritstier K; de Weerd V; Groenewoud A; Uitterlinden AG; Look MP; Klijn JG; Sleijfer S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2012 Jun; 133(3):843-51. PubMed ID: 21748294
[TBL] [Abstract] [Full Text] [Related]
19. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.
Tapper W; Hammond V; Gerty S; Ennis S; Simmonds P; Collins A; ; Eccles D
Breast Cancer Res; 2008; 10(6):R108. PubMed ID: 19094228
[TBL] [Abstract] [Full Text] [Related]
